Pancreatic cancer vaccine with chemotherapy before/around surgery
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This early-stage trial tests a personalized immune “vaccine” made from dendritic cells, given alongside standard chemotherapy for pancreatic cancer that may be removable by surgery (resectable or borderline resectable). If it works, it may help your immune system better recognize and attack the cancer around the time of treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign informed consent
- Your pancreatic cancer diagnosis is confirmed as adenocarcinoma or adenosquamous cancer, and it is considered potentially operable (resectable or borderline resectable), not stage IV
- Your blood counts and organ function (kidneys, liver, bone marrow) are strong enough for treatment
- You can do daily activities at about a level 2 or better (not fully bedridden)
- You can follow pregnancy-prevention rules (if able to become pregnant) and avoid donating blood during the study
- You do not have certain infections or immune problems that could interfere with the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized neoantigen vaccine given along with an anti-PD1 drug (pembrolizumab) and chemotherapy after surgery for pancreatic cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This study tests a personalized vaccine made from your own tumor, combined with a drug that helps your immune system fight cancer cells. The goal is to see if this approach can help prevent your pancreatic cancer from coming back after surgery.
This trial combines a new vaccine (XH001) with chemotherapy after surgery for pancreatic cancer. The vaccine aims to train your immune system to fight any remaining cancer cells, potentially lowering the chance of the cancer coming back.
This trial tests a combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery for pancreatic cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests a personalized mRNA vaccine (made from your tumor's unique markers) combined with standard chemotherapy after surgery for pancreatic cancer. The goal is to see if the vaccine can help prevent the cancer from coming back.
This trial tests giving a combination of an oncolytic virus, immunotherapy (PD-1 inhibitor), and chemotherapy before surgery to shrink pancreatic tumors and make them easier to remove. The goal is to improve outcomes for people with borderline resectable or locally advanced pancreatic cancer.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.